Dongwha Pharmaceutical said Tuesday that it has signed an agreement with Takeda Korea to market and distribute the latter’s gastroesophageal reflux disease (GERD) treatments—Dexilant DR Capsule 30 mg (dexlansoprazole), Dexilant DR Capsule 60 mg, Lanston LFDT Tablet 15 mg (lansoprazole), and Lanston LFTD Tablet 30 mg—exclusively in Korea.
Under the agreement, Dongwha Pharm will be in charge of marketing and distribution to strengthen the competitiveness of both products.
Corporate identities of Dongwha Pharmaceutical and Takeda Korea (Credit: Getty Images)
Corporate identities of Dongwha Pharmaceutical and Takeda Korea (Credit: Getty Images)
Dexilant is a PPI (proton pump inhibitor) treatment that utilizes Dual Delayed Release (DDR) technology to be absorbed into the body in two doses. This provides a 24-hour continuous effect with only one daily dose. It also has the advantage of being taken with or without meals.
Lanston LFDT has a wide range of indications for stomach acid-related conditions, and some indications can be prescribed for pediatric patients as young as one year of age.
According to Dongwha Pharm, its special formulation allows it to be taken without water, and its strawberry flavor enhances patient compliance.
“This exclusive sales and distribution agreement with Takeda Korea provides us with an important opportunity to expand the market share of Dexilant and Lanston and drive a successful sales strategy,” a Dongwha Pharm official said. “Donghwa Pharmaceutical adheres to the industry's highest standards of fair trade and ethical management principles, and we plan to strengthen the trust of consumers and the medical community.”
A Takeda Korea official said, “This collaboration marks an important milestone in our contribution to the Korean digestive therapeutics market. We will continue to build best collaboration practices with Dongwha Pharmaceutical based on our corporate philosophy of prioritizing patient health and our core value of ‘Integrity.’”
tweet
Related articles
Dongwha Pharm sues Hironic for ₩12 bil. deposit over failed acquisition
Kim Chan-hyuk kch@docdocdoc.co.kr
[See Other Articles](/news/articleList.html?sc_area=I&sc_word=Kim Chan-hyuk&view_type=sm)
Copyright © KBR Unauthorized reproduction, redistribution prohibited